Author Correction: Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial

IF 58.7 1区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Nature Medicine Pub Date : 2025-06-26 DOI:10.1038/s41591-025-03852-y

Yago Nieto, Pinaki Banerjee, Indreshpal Kaur, Rafet Basar, Ye Li, May Daher, Hind Rafei, Lucila N. Kerbauy, Mecit Kaplan, David Marin, Lori Griffin, Melissa Barnett, Roland Bassett, Nadima Uprety, Rejeena Shrestha, Francia Reyes Silva, Sanjida Islam, Christina Ganesh, Zephanie Borneo, Jeremy Ramdial, Alejandro Ramirez, Chitra Hosing, Amin Alousi, Uday Popat, Muzaffar Qazilbash, Sairah Ahmed, Swaminathan Iyer, Tania P. Sainz, Francisco Vega, Natalie W. Fowlkes, Karenza Alexis, Michael Emig, Andreas Harstrick, Andre Overesch, Elizabeth J. Shpall, Katayoun Rezvani

引用次数: 0

Abstract

Correction to: Nature Medicine https://doi.org/10.1038/s41591-025-03640-8, published online 4 April 2025.

查看原文本刊更多论文

作者更正：具有双特异性先天细胞接合物的异体NK细胞治疗难治性复发淋巴瘤：一项一期试验

更正：Nature Medicine https://doi.org/10.1038/s41591-025-03640-8，于2025年4月4日在线发布。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Medicine 医学-生化与分子生物学

CiteScore

100.90

自引率

0.70%

发文量

525

审稿时长

1 months

期刊介绍： Nature Medicine is a monthly journal publishing original peer-reviewed research in all areas of medicine. The publication focuses on originality, timeliness, interdisciplinary interest, and the impact on improving human health. In addition to research articles, Nature Medicine also publishes commissioned content such as News, Reviews, and Perspectives. This content aims to provide context for the latest advances in translational and clinical research, reaching a wide audience of M.D. and Ph.D. readers. All editorial decisions for the journal are made by a team of full-time professional editors. Nature Medicine consider all types of clinical research, including: -Case-reports and small case series -Clinical trials, whether phase 1, 2, 3 or 4 -Observational studies -Meta-analyses -Biomarker studies -Public and global health studies Nature Medicine is also committed to facilitating communication between translational and clinical researchers. As such, we consider “hybrid” studies with preclinical and translational findings reported alongside data from clinical studies.